Device Trial Radar · NCT05117840
Screening for High Frequency Malignant Disease
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12,000
Planned (sponsor's estimate)
Start
Jan 13, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Guardant Health, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 11, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Conditions
- Lung Cancer
Interventions
Low-dose CT scanDevice
Standard of care screening for individuals at high-risk of lung cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Performance characteristics of Guardant LUNAR-2 testTime frame: 36 months
Locations
143 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham Lung Health Center
Birmingham, Alabama
142 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.